NCT06613425 Clinical Study of Combined Platelet Transfusion
| NCT ID | NCT06613425 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | The General Hospital of Western Theater Command |
| Condition | Hematologic Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2025-07-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 86 participants in total. It began in 2024-08-01 with a primary completion date of 2025-07-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Platelet transfusion is an irreplaceable and important treatment method for clinical prevention and treatment of thrombocytopenia or platelet dysfunction. Due to various factors, it is difficult to achieve platelet ABO complete homotypic transfusion in clinical practice. When ABO-compatible platelets cannot be obtained, plasma-reduced platelets, platelets with low anti-A or anti-B titers are often used in clinical practice to reduce the risk of ABO-incompatible platelet-compatible transfusion reactions. The combined platelets prepared in this study can achieve ABO primary and secondary side compatible infusion.
Eligibility Criteria
Inclusion Criteria: * 1\. Aged 18-65 years; 2. Disease treatment in the research hospital; 3. Applied for platelet transfusion therapy. Exclusion Criteria: * 1\. One month before the start of this study, he participated in other clinical trials of drugs and instruments related to platelet transfusion efficacy; 2. Without platelet transfusion indications; 3. Only received platelet transfusion in the outpatient department and left the hospital without efficacy evaluation after transfusion; 4. Gave up platelet transfusion therapy for any reason after enrollment; 5. Transferred or discharged from hospital for any reason before platelet transfusion after enrollment; 6. Did not receive combined platelet transfusion during the 6-month treatment period after enrollment
Contact & Investigator
zhang li
PRINCIPAL INVESTIGATOR
The General Hospital of Weastern Theater Command
Frequently Asked Questions
Who can join the NCT06613425 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Hematologic Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06613425 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06613425 currently recruiting?
Yes, NCT06613425 is actively recruiting participants. Contact the research team at 1062747632@qq.com for enrollment information.
Where is the NCT06613425 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06613425 clinical trial?
NCT06613425 is sponsored by The General Hospital of Western Theater Command. The principal investigator is zhang li at The General Hospital of Weastern Theater Command. The trial plans to enroll 86 participants.